Cidara Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Cidara Therapeutics (NASDAQ: CDTX) announced that its President and CEO, Jeffrey Stein, Ph.D., will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on August 11, 2021, at 4:40 PM ET. The event will feature a live audio webcast available on the company's website. Cidara focuses on developing long-acting therapeutics for serious fungal and viral infections, highlighting its lead antifungal candidate, rezafungin, and its antiviral platform, Cloudbreak®.

News Market Reaction – CDTX

-0.59%

-0.59% Session move

In the trading session that priced this news, CDTX declined 0.59%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021.

Panel Information:
Date:	Wednesday, August 11, 2021
Time:	4:40 PM ET
Webcast:	A live audio webcast and replay of the presentation will be available in the Investors section on the company’s website at www.cidara.com.

About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Patrick Bursey
LifeSci Communications
(203) 430-9545
pbursey@lifescicomms.com

FAQ

What is the date and time of Cidara Therapeutics' panel discussion at the 2021 Wedbush PacGrow Healthcare Conference?

The panel discussion will take place on August 11, 2021, at 4:40 PM ET.

Where can I watch the Cidara Therapeutics panel discussion live?

The panel discussion will be available via a live audio webcast on Cidara's website.

What is Cidara Therapeutics' main focus in their development efforts?

Cidara is focused on developing long-acting therapeutics for serious fungal and viral infections.

What is the lead candidate of Cidara Therapeutics?

Cidara's lead antifungal candidate is rezafungin.

What platform does Cidara Therapeutics use for its antiviral candidates?

Cidara utilizes its proprietary Cloudbreak® antiviral platform for developing its antiviral candidates.